Scientists test new prostate disease drug

Mar 27, 2008

A Canadian-headquartered biopharmaceutical company is conducting the second Phase 3 study of a new drug designed to treat prostate disease.

Aeterna Zentaris Inc. said the double-blind study to be conducted in Europe will test the clinical effectiveness of cetrorelix, a luteinizing hormone-releasing drug for the treatment of benign prostatic hyperplasia, or BPH -- a non-cancerous enlargement of the prostate that causes disturbances in urination.

In the second Phase 3 study, 400 male patients will enter a four-week, no-treatment observation period and then be randomly assigned to either receive cetrorelix or a placebo. Effectiveness will based on a test that measures the severity and stability of voiding prostate symptoms.

The company's first study of the effectiveness of cetrorelix began in April 2007 and is continuing in Canada, Europe and the United States.

Copyright 2008 by United Press International

Explore further: New evidence confirms link between newer contraceptive pills and higher clot risks

Related Stories

South American parrot in trouble: researchers

3 hours ago

A South American parrot with a wine-colored chest is in deep trouble, with its population down to some 3,000 and a habitat reduced to a speck of what it once was, researchers said Tuesday.

Recommended for you

US appeals court upholds delay in Alzheimer's drug swap

May 22, 2015

A federal appeals court has rejected a drug manufacturer's appeal and affirmed a judge's order that Actavis PLC keep distributing its widely used Alzheimer's medication until after its patent expires this summer.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.